BR0012676A - Métodos para tratamento de tumores resistentes a terapia - Google Patents

Métodos para tratamento de tumores resistentes a terapia

Info

Publication number
BR0012676A
BR0012676A BR0012676-4A BR0012676A BR0012676A BR 0012676 A BR0012676 A BR 0012676A BR 0012676 A BR0012676 A BR 0012676A BR 0012676 A BR0012676 A BR 0012676A
Authority
BR
Brazil
Prior art keywords
enzyme
cell
methods
prodrug
resistant tumors
Prior art date
Application number
BR0012676-4A
Other languages
English (en)
Inventor
H Michael Shepard
Original Assignee
Newbiotics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newbiotics Inc filed Critical Newbiotics Inc
Publication of BR0012676A publication Critical patent/BR0012676A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODOS PARA TRATAMENTO DE TUMORES RESISTENTES A TERAPIA". Esta invenção fornece um método para seletivamente inibir uma célula patológica, em que a célula é caracterizada por expressão de uma enzima de ativação intracelular endógena e onde a enzima não é desativada por um composto de pró-droga de substrato. O método requer contatar a célula com uma quantidade eficaz do composto de substrato, desse modo seletivamente inibindo a proliferação da célula patológica. Esta invenção também fornece um método para análise de pró-drogas seletivamente convertidas a uma toxina em uma célula por uma enzima contatando-se pelo menos duas células testes que expressam um enzima intracelular endógena com a pró-droga candidata da mesma ou diferente espécies e ensaiando-se a ativação da pró-droga em agentes tóxicos pela enzima intracelular endógena.
BR0012676-4A 1999-07-22 2000-07-21 Métodos para tratamento de tumores resistentes a terapia BR0012676A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14536499P 1999-07-22 1999-07-22
US15385599P 1999-09-14 1999-09-14
PCT/US2000/020007 WO2001007088A2 (en) 1999-07-22 2000-07-21 Methods for treating therapy-resistant tumors

Publications (1)

Publication Number Publication Date
BR0012676A true BR0012676A (pt) 2003-07-01

Family

ID=26842895

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012676-4A BR0012676A (pt) 1999-07-22 2000-07-21 Métodos para tratamento de tumores resistentes a terapia

Country Status (11)

Country Link
US (1) US7419968B1 (pt)
EP (1) EP1200130A2 (pt)
JP (1) JP2003525866A (pt)
KR (1) KR20020059341A (pt)
CN (1) CN1391486A (pt)
AU (1) AU774492B2 (pt)
BR (1) BR0012676A (pt)
CA (1) CA2378187C (pt)
IL (1) IL147749A0 (pt)
MX (1) MXPA02000762A (pt)
WO (1) WO2001007088A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9708611D0 (en) * 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
CN1391486A (zh) 1999-07-22 2003-01-15 新生物公司 治疗对治疗有抗性的肿瘤的方法
AU6358900A (en) * 1999-07-22 2001-02-13 Newbiotics, Inc. Enzyme catalyzed anti-infective therapeutic agents
GB0009486D0 (en) 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
WO2002007780A2 (en) * 2000-07-20 2002-01-31 Newbiotics, Inc. Methods for identifying therapeutic targets
CA2441350A1 (en) 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions
US6987180B2 (en) 2002-02-07 2006-01-17 President And Fellows Of Harvard College Uridine analogs and techniques for making and using
DE10313035A1 (de) 2003-03-24 2004-10-07 Resprotect Gmbh Methode zur Verstärkung der apoptotischen Wirkung von Zytostatika ohne Erhöhung toxischer Nebenwirkungen
GB0609178D0 (en) 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
JP5769417B2 (ja) * 2007-08-16 2015-08-26 ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ 腫瘍細胞由来微小胞
US20100255514A1 (en) 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
JP2016514136A (ja) * 2013-03-15 2016-05-19 ザ ジェネラル ホスピタル コーポレイション グリシン、ミトコンドリア１炭素代謝、及びがん

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB982776A (en) * 1962-01-24 1965-02-10 Wellcome Found 2-deoxyuridines and their use in pharmaceutical compositions having anti-immune activity
JPS5017989B1 (pt) * 1970-12-24 1975-06-25
US4247544A (en) 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4267171A (en) 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
JPS5843993A (ja) 1981-09-09 1983-03-14 Yamasa Shoyu Co Ltd １−β−Ｄ−アラビノフラノシル−（Ｅ）−５−（２−ハロゲノビニル）ウラシル−５′−りん酸およびその製造法
EP0095294A1 (en) 1982-05-22 1983-11-30 Beecham Group Plc Deoxyuridine compounds, methods for preparing them and their use in medicine
DE3229169A1 (de) 1982-08-05 1984-02-09 Robugen GmbH Pharmazeutische Fabrik, 7300 Esslingen Verwendung von 5-alkylpyrimidinnukleosiden und deren derivate als zytostatika
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
RO88451A2 (ro) 1984-06-05 1986-01-30 Intreprinderea De Antibiotice,Ro Derivati ai acidului 7-aminocefalosporanic si procedeu de preparare aacestora
US5212291A (en) * 1986-10-23 1993-05-18 American Cyanamid Company Anthracycline derivatives as solubilized pro-drugs
US5116827A (en) * 1986-10-23 1992-05-26 American Cyanamid Company Quinolinecarboxylic acid derivatives as solubilized pro-drugs
US5077282A (en) * 1986-10-23 1991-12-31 American Cyanamid Company Solubilized pro-drugs
US5070082A (en) * 1986-10-23 1991-12-03 American Cyanamid Company Solubilized pro-drugs
US5077283A (en) * 1986-10-23 1991-12-31 American Cyanamid Company Solubilized imidazole pro-drugs
US4963533A (en) 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5116822A (en) 1986-10-24 1992-05-26 Stichting Rega Vzw Therapeutic application of dideoxycytidinene
NL8700366A (nl) 1987-02-13 1988-09-01 Stichting Rega V Z W Combinatie van fu met bvdu als middel tegen adenocarcinoom.
US5085983A (en) 1988-08-19 1992-02-04 City Of Hope Detection of human tumor progression and drug resistance
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
JPH01301690A (ja) 1987-10-08 1989-12-05 Stichting Rega Vzw 抗ｈｉｖ活性をもつ３’−アジド−２，６−ジアミノプリン−２’，３’−ジデオキシリボシド
JPH01265099A (ja) 1987-10-08 1989-10-23 Stichting Rega Vzw 抗ｈｉｖ活性をもつ３’，−フルオロプリン−２’，３’−ジデオキシリボシド類
US5338659A (en) 1991-04-02 1994-08-16 Terrapin Technologies, Inc. Method for determining analyte concentration by cross-reactivity profiling
US5217869A (en) 1987-10-13 1993-06-08 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US4963263A (en) 1988-03-24 1990-10-16 Terrapin Technologies, Inc. Method of identity analyte-binding peptides
US5300425A (en) 1987-10-13 1994-04-05 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US5133866A (en) 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
EP0316592A3 (en) 1987-11-13 1990-09-19 Stichting REGA V.Z.W. 3'-fluoro-2',3'-dideoxyuridine, and its therapeutic application
CA1317291C (en) 1987-12-14 1993-05-04 Naeem Botros Hanna Antitumor 6-sulfenamide, 6-sulfinamide and 6-sulfonamide purines, purine nucleosides, purine nucleotides and related compounds
WO1989008115A1 (fr) * 1988-02-24 1989-09-08 Institut De Recherches Chimiques Et Biologiques Ap NOUVEAUX DERIVES DE LA DEOXY-2'-URIDINE SUBSTITUEE EN POSITION 5, 3' ou 5' PAR DES GROUPEMENTS alpha-AMINO ACYLES, PROCEDE POUR LEUR OBTENTION ET MEDICAMENTS LES CONTENANT
WO1990003978A1 (en) 1988-10-03 1990-04-19 Stichting Rega Vzw 5-halogeno-3'-fluoro-2',3'-dideoxyuridine compounds and their therapeutic application
US5596018A (en) 1988-12-28 1997-01-21 Toray Industries, Inc. Antiviral agents against aids-causing virus
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
SK280313B6 (sk) 1990-04-24 1999-11-08 �Stav Organick� Chemie A Biochemie Av �R N-(3-fluór-2-fosfonylmetoxypropyl)deriváty purínov
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5137724A (en) 1990-05-23 1992-08-11 Stichting Rega Vzw Combinations of TS-inhibitors and viral TK-inhibitors in antiherpetic medicines
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
WO1992019767A1 (en) 1991-04-29 1992-11-12 Terrapin Technologies, Inc. Methods to profile and treat abnormal cells
US5556942A (en) 1991-04-29 1996-09-17 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
AU1787492A (en) 1991-05-16 1992-12-30 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
EP0530407B1 (en) 1991-09-04 1996-06-05 Stichting REGA V.Z.W. Substituted, nucleoside derivatives, methods for their preparation and pharmaceutical compositions containing them
US5233031A (en) 1991-09-23 1993-08-03 University Of Rochester Phosphoramidate analogs of 2'-deoxyuridine
US5879700A (en) 1991-10-15 1999-03-09 Hostetler; Karl Y. Nucleoside analogue phosphates for topical use
US5274162A (en) 1991-12-13 1993-12-28 Arnold Glazier Antineoplastic drugs with bipolar toxification/detoxification functionalities
CA2126979A1 (en) * 1991-12-31 1993-07-22 Eliezer Rapaport Antiparasitic oligonucleotides active against drug resistant malaria
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
US5668828A (en) * 1992-05-08 1997-09-16 Sanconix, Inc. Enhanced frequency agile radio
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5516631A (en) 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
IL105244A (en) * 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US5502037A (en) 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
WO1995008556A1 (en) * 1993-09-21 1995-03-30 Amersham International Plc Reagents comprising chimeric molecules of nucleic acids and nucleic acid analogs
US5908919A (en) 1993-10-01 1999-06-01 Terrapin Technologies Urethane mediated, GST specific molecular release systems
GB9323008D0 (en) * 1993-11-05 1994-01-05 Connors Thomas Improvements relating to cancer therapy
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5521161A (en) 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
US5643893A (en) 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
GB9415167D0 (en) * 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
US5556992A (en) * 1994-09-02 1996-09-17 Universite De Montreal Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias
US5968910A (en) 1994-11-30 1999-10-19 Jan M. R. Balzarini Compositions containing two or three inhibitors of different HIV reverse transcriptases
DK0806956T3 (da) 1995-02-01 2003-01-06 Resprotect Gmbh Anvendelse af 5-substituerede nucleosider til hæmning af resistensdannelse ved cytostatikabehandling
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
MY114302A (en) 1995-04-19 2002-09-30 Ihara Chemical Ind Co Benzylsulfide derivative, process for its production and pesticide
US5856464A (en) * 1995-06-07 1999-01-05 Lajolla Pharmaceutical Company Selective capping solution phase oligonucleotide synthesis
US5981507A (en) 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
US5880097A (en) 1996-01-04 1999-03-09 Terrapin Techologies, Inc. Tethered prodrugs
US6149904A (en) * 1996-01-31 2000-11-21 The Regents Of The University Of California Method for inhibiting tumor cell growth by administering to tumor cells expressing a nucleic acid encoding a connexin and a pro-drug
RU2111970C1 (ru) 1996-06-25 1998-05-27 Иван Игоревич Федоров 3'-оксимино-2',3'-дидезоксинуклеозиды
GB9708611D0 (en) 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
WO1999006072A1 (en) * 1997-07-30 1999-02-11 Boehringer Mannheim Corporation Cyclized prodrugs
CN1307421C (zh) * 1997-08-08 2007-03-28 塞米得肿瘤学美国公司 克服生物及化学治疗抗性的方法与组合物
CA2307807C (en) * 1997-10-23 2008-09-02 Andrea G. Bodnar Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
JP2001522034A (ja) 1997-10-30 2001-11-13 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， リプレゼンテッド バイ ザ セクレタリー オブ ヘルス アンド ヒューマン サービシーズ 画像化および処置適用のためのヌクレオシド
DE69900841T2 (de) * 1998-01-23 2002-10-02 Newbiotics Inc Durch enzymkatalyse erhaltene therapeutische substanzen.
GB9821058D0 (en) 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
NZ512171A (en) * 1998-12-11 2004-07-30 Medarex Inc Prodrug compound comprising a therapeutic agent, an oligopeptide with a non-genetically encoded amino acid, a stabilizing group and optionally a linker group
CA2379988C (en) * 1999-07-22 2010-10-19 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
AU6358900A (en) * 1999-07-22 2001-02-13 Newbiotics, Inc. Enzyme catalyzed anti-infective therapeutic agents
US6683061B1 (en) * 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
CN1391486A (zh) 1999-07-22 2003-01-15 新生物公司 治疗对治疗有抗性的肿瘤的方法
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
GB0009486D0 (en) 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
GB0011203D0 (en) 2000-05-09 2000-06-28 Univ Cardiff Chemical compounds
US20020147175A1 (en) * 2000-11-16 2002-10-10 Shepard H. Michael Synergistic ECTA compositions
CA2441350A1 (en) * 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions

Also Published As

Publication number Publication date
EP1200130A2 (en) 2002-05-02
CA2378187C (en) 2011-09-13
US7419968B1 (en) 2008-09-02
IL147749A0 (en) 2002-08-14
JP2003525866A (ja) 2003-09-02
CN1391486A (zh) 2003-01-15
MXPA02000762A (es) 2002-08-20
AU774492B2 (en) 2004-07-01
CA2378187A1 (en) 2001-02-01
KR20020059341A (ko) 2002-07-12
WO2001007088A3 (en) 2001-11-15
WO2001007088A2 (en) 2001-02-01
AU6231800A (en) 2001-02-13

Similar Documents

Publication Publication Date Title
BR0012676A (pt) Métodos para tratamento de tumores resistentes a terapia
PT1045897E (pt) Agentes terapeuticos por catalise enzimatica
Nagatsu et al. Immunofluorescent studies on tyrosine hydroxylase: application for its axoplasmic transport
Rickard et al. Binding of pp170 to microtubules is regulated by phosphorylation.
BR0115715A (pt) Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
DE69737684D1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
ATE323720T1 (de) Zinkfinger-bindungsdomänen für gnn
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
WO2005010215A3 (en) Methods for identifying tolerance modulatory compounds and uses therefor
DE69840216D1 (de) Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden
PT1143955E (pt) Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
PT1218494E (pt) Composicoes e metodos para inibir a paragem do ciclo celular g2 e para sensibilizar celulas perante agentes que danificam o adn
ATE226254T1 (de) Reagenz zur behandlung von arthritischen zustaenden
ATE58900T1 (de) Diaryldiazolylmethane.
Zappia et al. Mechanism of propylamine-transfer reactions. Kinetic and inhibition studies on spermidine synthase from Escherichia coli.
BRPI0606577A2 (pt) métodos de tratamento ou prevenção de infestação de ectoparasitas em hospedeiro de planta e de inibição da eclosão de ovo de ectoparasita
BR0115689A (pt) Análise de expressão de inibidor de diferenciação de ácidos nucléicos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
BR9909356A (pt) Substrato cromogênico que permite detectar a presença da atividade enzimática de pelo menos uma enzima, processo de detecção de uma atividade enzimática por meio de substratos, uso de substrato, e, dispositivo de identificação
Kureishi et al. Regulation of Ca2+-independent smooth muscle contraction by alternative staurosporine-sensitive kinase
Chanda et al. Polyamines in relation to human breast, rectal and squamous cell carcinoma
Waymire et al. Lack of regulation of aromatic l‐amino acid decarboxylase in intact bovine chromaffin cells
BR0115728A (pt) Análise da expressão de ácidos nucléicos kiaa e polipeptìdeos úteis no diagnóstico e tratamento de cáncer de próstata
BR0012135A (pt) Métodos de tratamento de infecções de fungos com inibidores de enzima sintetase nad
DiSilvestro et al. Evaluation of (+)-catechin action on lysyl oxidase activity in aortic tissue

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: CELMED ONCOLOGY (USA), INC. (CA)

Free format text: ALTERADO DE: NEWBIOTICS, INC.

B25G Requested change of headquarter approved

Owner name: CELMED ONCOLOGY (USA), INC. (CA)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020050094969/RJ DE 08/09/2005.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.

B15K Others concerning applications: alteration of classification

Ipc: G01N 33/50 (2006.01), A61K 47/54 (2017.01), C12Q 1